Janet Robinson is an infectious disease, health security, public health, clinical, laboratory, health systems strengthening, quality assurance and regulatory specialist with more than 30 years’ experience in global public health, health security, pandemic preparedness, healthcare programming, health systems strengthening, human and animal health laboratory diagnostics, regulatory affairs/quality assurance and research. She is currently serving as a Portfolio Director within FHI 360’s Infectious Diseases Division and is responsible for driving growth, partnerships, innovations, and business development for the division. Previously she served as FHI 360’s Director of Emerging Infectious Diseases and Health Security leading a global portfolio of global health security, infectious diseases and health systems strengthening projects spanning Asia, Africa, and South America. Ms. Robinson has a track record of succeeding with strategic investments, first with the creation of the Laboratory Sciences Division and later with the establishment of the Emerging Infectious Diseases and Health Security Division.
As part of her many roles within FHI 360, Ms. Robinson has spear headed business development and growth efforts, securing over $110M in funding from a diverse range of USG and non-USG donors. She has driven the creation of a diverse and robust portfolio of projects, building the capacity of a global team of over 130 staff to implement awards. To support this work, she has extensive proposal design and development, operational, and financial skills. Ms. Robinson is a strategic thinker and has demonstrated her ability to create and design collaborative relationships, partnerships, and solutions to address complex public health issues. Ms. Robinson has led teams and projects and research that have sought to address numerous infectious diseases including HIV, TB, malaria, dengue, avian influenza, severe human influenza, COVID-19, Zika, Chikungunya, polio, ebola, diarrheal diseases, sepsis, Lassa fever, meningitis, Japanese Encephalitis and other zoonotic and vector-borne diseases and parasites. Her work has also included addressing the effect of climate change on health systems using a multisectoral approach. For over ten years, she led the Asia Pacific global research team based out of Bangkok, Thailand.
Before joining FHI 360, Ms. Robinson held several positions with Unipath Diagnostics Inc. (private sector pharmaceutical company), including Director of Clinical and Medical Affairs. Ms. Robinson is a certified clinical pathologist (specialism medical microbiology) and is a Fellow of the Institute of Biomedical and Laboratory Sciences (UK). Ms. Robinson is a steering group member of the Global Health Security Agenda Consortium. She is an invited member of several international laboratory working groups including laboratory strengthening working groups run by the Clinical Laboratory Standards Institute, the American Society of Microbiology, and the College of American Pathologists. She is also a member of the US FDA Advisory Committee for Microbiology. She authored the Laboratory Diagnostics chapter of the 23rd and 24th edition of Manson’s Tropical Diseases.
